Global Rare Kidney Diseases Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Rare Kidney Diseases Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Rare Kidney Diseases Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Drug Class and by Distribution Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Rare Kidney Diseases Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Rare Kidney Diseases Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Rare Kidney Diseases Treatment market size and forecasts, by Drug Class and by Distribution Channel, in consumption value ($ Million), 2018-2029
Global Rare Kidney Diseases Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rare Kidney Diseases Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rare Kidney Diseases Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals, Inc., Amicus Therapeutics, Inc. and Shire (Takeda Pharmaceutical Company Limited), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Rare Kidney Diseases Treatment market is split by Drug Class and by Distribution Channel. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Drug Class and by Distribution Channel. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Drug Class
Chapter 1, to describe Rare Kidney Diseases Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Rare Kidney Diseases Treatment, with revenue, gross margin and global market share of Rare Kidney Diseases Treatment from 2018 to 2023.
Chapter 3, the Rare Kidney Diseases Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Drug Class and application, with consumption value and growth rate by Drug Class, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Rare Kidney Diseases Treatment market forecast, by regions, drug class and distribution channel, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Rare Kidney Diseases Treatment.
Chapter 13, to describe Rare Kidney Diseases Treatment research findings and conclusion.
This report is a detailed and comprehensive analysis for global Rare Kidney Diseases Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Drug Class and by Distribution Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Rare Kidney Diseases Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Rare Kidney Diseases Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Rare Kidney Diseases Treatment market size and forecasts, by Drug Class and by Distribution Channel, in consumption value ($ Million), 2018-2029
Global Rare Kidney Diseases Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rare Kidney Diseases Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rare Kidney Diseases Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals, Inc., Amicus Therapeutics, Inc. and Shire (Takeda Pharmaceutical Company Limited), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Rare Kidney Diseases Treatment market is split by Drug Class and by Distribution Channel. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Drug Class and by Distribution Channel. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Drug Class
- Enzyme Replacement Therapy
- Monoclonal Antibodies
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
- Calliditas Therapeutics AB
- GSK plc
- Aurinia Pharmaceuticals, Inc.
- Amicus Therapeutics, Inc.
- Shire (Takeda Pharmaceutical Company Limited)
- Sanofi
- Advicenne
- Alexion Pharmaceuticals, Inc.
- Horizon Therapeutics plc
- Otsuka Pharmaceutical Co., Ltd.
- Reata Pharmaceuticals, Inc.
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Rare Kidney Diseases Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Rare Kidney Diseases Treatment, with revenue, gross margin and global market share of Rare Kidney Diseases Treatment from 2018 to 2023.
Chapter 3, the Rare Kidney Diseases Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Drug Class and application, with consumption value and growth rate by Drug Class, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Rare Kidney Diseases Treatment market forecast, by regions, drug class and distribution channel, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Rare Kidney Diseases Treatment.
Chapter 13, to describe Rare Kidney Diseases Treatment research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Rare Kidney Diseases Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Rare Kidney Diseases Treatment by Drug Class
1.3.1 Overview: Global Rare Kidney Diseases Treatment Market Size by Drug Class: 2018 Versus 2022 Versus 2029
1.3.2 Global Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class in 2022
1.3.3 Enzyme Replacement Therapy
1.3.4 Monoclonal Antibodies
1.3.5 Others
1.4 Global Rare Kidney Diseases Treatment Market by Distribution Channel
1.4.1 Overview: Global Rare Kidney Diseases Treatment Market Size by Distribution Channel: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Sales
1.5 Global Rare Kidney Diseases Treatment Market Size & Forecast
1.6 Global Rare Kidney Diseases Treatment Market Size and Forecast by Region
1.6.1 Global Rare Kidney Diseases Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Rare Kidney Diseases Treatment Market Size by Region, (2018-2029)
1.6.3 North America Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Calliditas Therapeutics AB
2.1.1 Calliditas Therapeutics AB Details
2.1.2 Calliditas Therapeutics AB Major Business
2.1.3 Calliditas Therapeutics AB Rare Kidney Diseases Treatment Product and Solutions
2.1.4 Calliditas Therapeutics AB Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Calliditas Therapeutics AB Recent Developments and Future Plans
2.2 GSK plc
2.2.1 GSK plc Details
2.2.2 GSK plc Major Business
2.2.3 GSK plc Rare Kidney Diseases Treatment Product and Solutions
2.2.4 GSK plc Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GSK plc Recent Developments and Future Plans
2.3 Aurinia Pharmaceuticals, Inc.
2.3.1 Aurinia Pharmaceuticals, Inc. Details
2.3.2 Aurinia Pharmaceuticals, Inc. Major Business
2.3.3 Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.3.4 Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Aurinia Pharmaceuticals, Inc. Recent Developments and Future Plans
2.4 Amicus Therapeutics, Inc.
2.4.1 Amicus Therapeutics, Inc. Details
2.4.2 Amicus Therapeutics, Inc. Major Business
2.4.3 Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.4.4 Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Amicus Therapeutics, Inc. Recent Developments and Future Plans
2.5 Shire (Takeda Pharmaceutical Company Limited)
2.5.1 Shire (Takeda Pharmaceutical Company Limited) Details
2.5.2 Shire (Takeda Pharmaceutical Company Limited) Major Business
2.5.3 Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Product and Solutions
2.5.4 Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments and Future Plans
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Rare Kidney Diseases Treatment Product and Solutions
2.6.4 Sanofi Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sanofi Recent Developments and Future Plans
2.7 Advicenne
2.7.1 Advicenne Details
2.7.2 Advicenne Major Business
2.7.3 Advicenne Rare Kidney Diseases Treatment Product and Solutions
2.7.4 Advicenne Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Advicenne Recent Developments and Future Plans
2.8 Alexion Pharmaceuticals, Inc.
2.8.1 Alexion Pharmaceuticals, Inc. Details
2.8.2 Alexion Pharmaceuticals, Inc. Major Business
2.8.3 Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.8.4 Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
2.9 Horizon Therapeutics plc
2.9.1 Horizon Therapeutics plc Details
2.9.2 Horizon Therapeutics plc Major Business
2.9.3 Horizon Therapeutics plc Rare Kidney Diseases Treatment Product and Solutions
2.9.4 Horizon Therapeutics plc Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Horizon Therapeutics plc Recent Developments and Future Plans
2.10 Otsuka Pharmaceutical Co., Ltd.
2.10.1 Otsuka Pharmaceutical Co., Ltd. Details
2.10.2 Otsuka Pharmaceutical Co., Ltd. Major Business
2.10.3 Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Product and Solutions
2.10.4 Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.11 Reata Pharmaceuticals, Inc.
2.11.1 Reata Pharmaceuticals, Inc. Details
2.11.2 Reata Pharmaceuticals, Inc. Major Business
2.11.3 Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.11.4 Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Reata Pharmaceuticals, Inc. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Rare Kidney Diseases Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Rare Kidney Diseases Treatment by Company Revenue
3.2.2 Top 3 Rare Kidney Diseases Treatment Players Market Share in 2022
3.2.3 Top 6 Rare Kidney Diseases Treatment Players Market Share in 2022
3.3 Rare Kidney Diseases Treatment Market: Overall Company Footprint Analysis
3.3.1 Rare Kidney Diseases Treatment Market: Region Footprint
3.3.2 Rare Kidney Diseases Treatment Market: Company Product Type Footprint
3.3.3 Rare Kidney Diseases Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY DRUG CLASS
4.1 Global Rare Kidney Diseases Treatment Consumption Value and Market Share by Drug Class (2018-2023)
4.2 Global Rare Kidney Diseases Treatment Market Forecast by Drug Class (2024-2029)
5 MARKET SIZE SEGMENT BY DISTRIBUTION CHANNEL
5.1 Global Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2023)
5.2 Global Rare Kidney Diseases Treatment Market Forecast by Distribution Channel (2024-2029)
6 NORTH AMERICA
6.1 North America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
6.2 North America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
6.3 North America Rare Kidney Diseases Treatment Market Size by Country
6.3.1 North America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
7.2 Europe Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
7.3 Europe Rare Kidney Diseases Treatment Market Size by Country
7.3.1 Europe Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.3 France Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
8.2 Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
8.3 Asia-Pacific Rare Kidney Diseases Treatment Market Size by Region
8.3.1 Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Region (2018-2029)
8.3.2 China Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.5 India Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
9.2 South America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
9.3 South America Rare Kidney Diseases Treatment Market Size by Country
9.3.1 South America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
10.2 Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
10.3 Middle East & Africa Rare Kidney Diseases Treatment Market Size by Country
10.3.1 Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Rare Kidney Diseases Treatment Market Drivers
11.2 Rare Kidney Diseases Treatment Market Restraints
11.3 Rare Kidney Diseases Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Rare Kidney Diseases Treatment Industry Chain
12.2 Rare Kidney Diseases Treatment Upstream Analysis
12.3 Rare Kidney Diseases Treatment Midstream Analysis
12.4 Rare Kidney Diseases Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Rare Kidney Diseases Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Rare Kidney Diseases Treatment by Drug Class
1.3.1 Overview: Global Rare Kidney Diseases Treatment Market Size by Drug Class: 2018 Versus 2022 Versus 2029
1.3.2 Global Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class in 2022
1.3.3 Enzyme Replacement Therapy
1.3.4 Monoclonal Antibodies
1.3.5 Others
1.4 Global Rare Kidney Diseases Treatment Market by Distribution Channel
1.4.1 Overview: Global Rare Kidney Diseases Treatment Market Size by Distribution Channel: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Sales
1.5 Global Rare Kidney Diseases Treatment Market Size & Forecast
1.6 Global Rare Kidney Diseases Treatment Market Size and Forecast by Region
1.6.1 Global Rare Kidney Diseases Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Rare Kidney Diseases Treatment Market Size by Region, (2018-2029)
1.6.3 North America Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Rare Kidney Diseases Treatment Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Calliditas Therapeutics AB
2.1.1 Calliditas Therapeutics AB Details
2.1.2 Calliditas Therapeutics AB Major Business
2.1.3 Calliditas Therapeutics AB Rare Kidney Diseases Treatment Product and Solutions
2.1.4 Calliditas Therapeutics AB Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Calliditas Therapeutics AB Recent Developments and Future Plans
2.2 GSK plc
2.2.1 GSK plc Details
2.2.2 GSK plc Major Business
2.2.3 GSK plc Rare Kidney Diseases Treatment Product and Solutions
2.2.4 GSK plc Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GSK plc Recent Developments and Future Plans
2.3 Aurinia Pharmaceuticals, Inc.
2.3.1 Aurinia Pharmaceuticals, Inc. Details
2.3.2 Aurinia Pharmaceuticals, Inc. Major Business
2.3.3 Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.3.4 Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Aurinia Pharmaceuticals, Inc. Recent Developments and Future Plans
2.4 Amicus Therapeutics, Inc.
2.4.1 Amicus Therapeutics, Inc. Details
2.4.2 Amicus Therapeutics, Inc. Major Business
2.4.3 Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.4.4 Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Amicus Therapeutics, Inc. Recent Developments and Future Plans
2.5 Shire (Takeda Pharmaceutical Company Limited)
2.5.1 Shire (Takeda Pharmaceutical Company Limited) Details
2.5.2 Shire (Takeda Pharmaceutical Company Limited) Major Business
2.5.3 Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Product and Solutions
2.5.4 Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments and Future Plans
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Rare Kidney Diseases Treatment Product and Solutions
2.6.4 Sanofi Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sanofi Recent Developments and Future Plans
2.7 Advicenne
2.7.1 Advicenne Details
2.7.2 Advicenne Major Business
2.7.3 Advicenne Rare Kidney Diseases Treatment Product and Solutions
2.7.4 Advicenne Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Advicenne Recent Developments and Future Plans
2.8 Alexion Pharmaceuticals, Inc.
2.8.1 Alexion Pharmaceuticals, Inc. Details
2.8.2 Alexion Pharmaceuticals, Inc. Major Business
2.8.3 Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.8.4 Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
2.9 Horizon Therapeutics plc
2.9.1 Horizon Therapeutics plc Details
2.9.2 Horizon Therapeutics plc Major Business
2.9.3 Horizon Therapeutics plc Rare Kidney Diseases Treatment Product and Solutions
2.9.4 Horizon Therapeutics plc Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Horizon Therapeutics plc Recent Developments and Future Plans
2.10 Otsuka Pharmaceutical Co., Ltd.
2.10.1 Otsuka Pharmaceutical Co., Ltd. Details
2.10.2 Otsuka Pharmaceutical Co., Ltd. Major Business
2.10.3 Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Product and Solutions
2.10.4 Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.11 Reata Pharmaceuticals, Inc.
2.11.1 Reata Pharmaceuticals, Inc. Details
2.11.2 Reata Pharmaceuticals, Inc. Major Business
2.11.3 Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
2.11.4 Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Reata Pharmaceuticals, Inc. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Rare Kidney Diseases Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Rare Kidney Diseases Treatment by Company Revenue
3.2.2 Top 3 Rare Kidney Diseases Treatment Players Market Share in 2022
3.2.3 Top 6 Rare Kidney Diseases Treatment Players Market Share in 2022
3.3 Rare Kidney Diseases Treatment Market: Overall Company Footprint Analysis
3.3.1 Rare Kidney Diseases Treatment Market: Region Footprint
3.3.2 Rare Kidney Diseases Treatment Market: Company Product Type Footprint
3.3.3 Rare Kidney Diseases Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY DRUG CLASS
4.1 Global Rare Kidney Diseases Treatment Consumption Value and Market Share by Drug Class (2018-2023)
4.2 Global Rare Kidney Diseases Treatment Market Forecast by Drug Class (2024-2029)
5 MARKET SIZE SEGMENT BY DISTRIBUTION CHANNEL
5.1 Global Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2023)
5.2 Global Rare Kidney Diseases Treatment Market Forecast by Distribution Channel (2024-2029)
6 NORTH AMERICA
6.1 North America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
6.2 North America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
6.3 North America Rare Kidney Diseases Treatment Market Size by Country
6.3.1 North America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
7.2 Europe Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
7.3 Europe Rare Kidney Diseases Treatment Market Size by Country
7.3.1 Europe Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.3 France Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
8.2 Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
8.3 Asia-Pacific Rare Kidney Diseases Treatment Market Size by Region
8.3.1 Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Region (2018-2029)
8.3.2 China Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.5 India Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
9.2 South America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
9.3 South America Rare Kidney Diseases Treatment Market Size by Country
9.3.1 South America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2029)
10.2 Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2029)
10.3 Middle East & Africa Rare Kidney Diseases Treatment Market Size by Country
10.3.1 Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Rare Kidney Diseases Treatment Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Rare Kidney Diseases Treatment Market Drivers
11.2 Rare Kidney Diseases Treatment Market Restraints
11.3 Rare Kidney Diseases Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Rare Kidney Diseases Treatment Industry Chain
12.2 Rare Kidney Diseases Treatment Upstream Analysis
12.3 Rare Kidney Diseases Treatment Midstream Analysis
12.4 Rare Kidney Diseases Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Rare Kidney Diseases Treatment Consumption Value by Drug Class, (USD Million), 2018 & 2022 & 2029
Table 2. Global Rare Kidney Diseases Treatment Consumption Value by Distribution Channel, (USD Million), 2018 & 2022 & 2029
Table 3. Global Rare Kidney Diseases Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Rare Kidney Diseases Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Calliditas Therapeutics AB Company Information, Head Office, and Major Competitors
Table 6. Calliditas Therapeutics AB Major Business
Table 7. Calliditas Therapeutics AB Rare Kidney Diseases Treatment Product and Solutions
Table 8. Calliditas Therapeutics AB Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Calliditas Therapeutics AB Recent Developments and Future Plans
Table 10. GSK plc Company Information, Head Office, and Major Competitors
Table 11. GSK plc Major Business
Table 12. GSK plc Rare Kidney Diseases Treatment Product and Solutions
Table 13. GSK plc Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. GSK plc Recent Developments and Future Plans
Table 15. Aurinia Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 16. Aurinia Pharmaceuticals, Inc. Major Business
Table 17. Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 18. Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Aurinia Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 20. Amicus Therapeutics, Inc. Company Information, Head Office, and Major Competitors
Table 21. Amicus Therapeutics, Inc. Major Business
Table 22. Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 23. Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Amicus Therapeutics, Inc. Recent Developments and Future Plans
Table 25. Shire (Takeda Pharmaceutical Company Limited) Company Information, Head Office, and Major Competitors
Table 26. Shire (Takeda Pharmaceutical Company Limited) Major Business
Table 27. Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Product and Solutions
Table 28. Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Shire (Takeda Pharmaceutical Company Limited) Recent Developments and Future Plans
Table 30. Sanofi Company Information, Head Office, and Major Competitors
Table 31. Sanofi Major Business
Table 32. Sanofi Rare Kidney Diseases Treatment Product and Solutions
Table 33. Sanofi Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Sanofi Recent Developments and Future Plans
Table 35. Advicenne Company Information, Head Office, and Major Competitors
Table 36. Advicenne Major Business
Table 37. Advicenne Rare Kidney Diseases Treatment Product and Solutions
Table 38. Advicenne Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Advicenne Recent Developments and Future Plans
Table 40. Alexion Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 41. Alexion Pharmaceuticals, Inc. Major Business
Table 42. Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 43. Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 45. Horizon Therapeutics plc Company Information, Head Office, and Major Competitors
Table 46. Horizon Therapeutics plc Major Business
Table 47. Horizon Therapeutics plc Rare Kidney Diseases Treatment Product and Solutions
Table 48. Horizon Therapeutics plc Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Horizon Therapeutics plc Recent Developments and Future Plans
Table 50. Otsuka Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 51. Otsuka Pharmaceutical Co., Ltd. Major Business
Table 52. Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Product and Solutions
Table 53. Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 55. Reata Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 56. Reata Pharmaceuticals, Inc. Major Business
Table 57. Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 58. Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Reata Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 60. Global Rare Kidney Diseases Treatment Revenue (USD Million) by Players (2018-2023)
Table 61. Global Rare Kidney Diseases Treatment Revenue Share by Players (2018-2023)
Table 62. Breakdown of Rare Kidney Diseases Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Rare Kidney Diseases Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 64. Head Office of Key Rare Kidney Diseases Treatment Players
Table 65. Rare Kidney Diseases Treatment Market: Company Product Type Footprint
Table 66. Rare Kidney Diseases Treatment Market: Company Product Application Footprint
Table 67. Rare Kidney Diseases Treatment New Market Entrants and Barriers to Market Entry
Table 68. Rare Kidney Diseases Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Rare Kidney Diseases Treatment Consumption Value (USD Million) by Drug Class (2018-2023)
Table 70. Global Rare Kidney Diseases Treatment Consumption Value Share by Drug Class (2018-2023)
Table 71. Global Rare Kidney Diseases Treatment Consumption Value Forecast by Drug Class (2024-2029)
Table 72. Global Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023)
Table 73. Global Rare Kidney Diseases Treatment Consumption Value Forecast by Distribution Channel (2024-2029)
Table 74. North America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 75. North America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 76. North America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 77. North America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 78. North America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 79. North America Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 80. Europe Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 81. Europe Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 82. Europe Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 83. Europe Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 84. Europe Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 87. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 88. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 89. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 90. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 91. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 92. South America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 93. South America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 94. South America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 95. South America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 96. South America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 97. South America Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 99. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 100. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 101. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 102. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 103. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 104. Rare Kidney Diseases Treatment Raw Material
Table 105. Key Suppliers of Rare Kidney Diseases Treatment Raw Materials
Table 1. Global Rare Kidney Diseases Treatment Consumption Value by Drug Class, (USD Million), 2018 & 2022 & 2029
Table 2. Global Rare Kidney Diseases Treatment Consumption Value by Distribution Channel, (USD Million), 2018 & 2022 & 2029
Table 3. Global Rare Kidney Diseases Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Rare Kidney Diseases Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Calliditas Therapeutics AB Company Information, Head Office, and Major Competitors
Table 6. Calliditas Therapeutics AB Major Business
Table 7. Calliditas Therapeutics AB Rare Kidney Diseases Treatment Product and Solutions
Table 8. Calliditas Therapeutics AB Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Calliditas Therapeutics AB Recent Developments and Future Plans
Table 10. GSK plc Company Information, Head Office, and Major Competitors
Table 11. GSK plc Major Business
Table 12. GSK plc Rare Kidney Diseases Treatment Product and Solutions
Table 13. GSK plc Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. GSK plc Recent Developments and Future Plans
Table 15. Aurinia Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 16. Aurinia Pharmaceuticals, Inc. Major Business
Table 17. Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 18. Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Aurinia Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 20. Amicus Therapeutics, Inc. Company Information, Head Office, and Major Competitors
Table 21. Amicus Therapeutics, Inc. Major Business
Table 22. Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 23. Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Amicus Therapeutics, Inc. Recent Developments and Future Plans
Table 25. Shire (Takeda Pharmaceutical Company Limited) Company Information, Head Office, and Major Competitors
Table 26. Shire (Takeda Pharmaceutical Company Limited) Major Business
Table 27. Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Product and Solutions
Table 28. Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Shire (Takeda Pharmaceutical Company Limited) Recent Developments and Future Plans
Table 30. Sanofi Company Information, Head Office, and Major Competitors
Table 31. Sanofi Major Business
Table 32. Sanofi Rare Kidney Diseases Treatment Product and Solutions
Table 33. Sanofi Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Sanofi Recent Developments and Future Plans
Table 35. Advicenne Company Information, Head Office, and Major Competitors
Table 36. Advicenne Major Business
Table 37. Advicenne Rare Kidney Diseases Treatment Product and Solutions
Table 38. Advicenne Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Advicenne Recent Developments and Future Plans
Table 40. Alexion Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 41. Alexion Pharmaceuticals, Inc. Major Business
Table 42. Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 43. Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 45. Horizon Therapeutics plc Company Information, Head Office, and Major Competitors
Table 46. Horizon Therapeutics plc Major Business
Table 47. Horizon Therapeutics plc Rare Kidney Diseases Treatment Product and Solutions
Table 48. Horizon Therapeutics plc Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Horizon Therapeutics plc Recent Developments and Future Plans
Table 50. Otsuka Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 51. Otsuka Pharmaceutical Co., Ltd. Major Business
Table 52. Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Product and Solutions
Table 53. Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 55. Reata Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 56. Reata Pharmaceuticals, Inc. Major Business
Table 57. Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Product and Solutions
Table 58. Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Reata Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 60. Global Rare Kidney Diseases Treatment Revenue (USD Million) by Players (2018-2023)
Table 61. Global Rare Kidney Diseases Treatment Revenue Share by Players (2018-2023)
Table 62. Breakdown of Rare Kidney Diseases Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Rare Kidney Diseases Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 64. Head Office of Key Rare Kidney Diseases Treatment Players
Table 65. Rare Kidney Diseases Treatment Market: Company Product Type Footprint
Table 66. Rare Kidney Diseases Treatment Market: Company Product Application Footprint
Table 67. Rare Kidney Diseases Treatment New Market Entrants and Barriers to Market Entry
Table 68. Rare Kidney Diseases Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Rare Kidney Diseases Treatment Consumption Value (USD Million) by Drug Class (2018-2023)
Table 70. Global Rare Kidney Diseases Treatment Consumption Value Share by Drug Class (2018-2023)
Table 71. Global Rare Kidney Diseases Treatment Consumption Value Forecast by Drug Class (2024-2029)
Table 72. Global Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023)
Table 73. Global Rare Kidney Diseases Treatment Consumption Value Forecast by Distribution Channel (2024-2029)
Table 74. North America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 75. North America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 76. North America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 77. North America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 78. North America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 79. North America Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 80. Europe Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 81. Europe Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 82. Europe Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 83. Europe Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 84. Europe Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 87. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 88. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 89. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 90. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 91. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 92. South America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 93. South America Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 94. South America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 95. South America Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 96. South America Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 97. South America Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Drug Class (2018-2023) & (USD Million)
Table 99. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Drug Class (2024-2029) & (USD Million)
Table 100. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2018-2023) & (USD Million)
Table 101. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Distribution Channel (2024-2029) & (USD Million)
Table 102. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 103. Middle East & Africa Rare Kidney Diseases Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 104. Rare Kidney Diseases Treatment Raw Material
Table 105. Key Suppliers of Rare Kidney Diseases Treatment Raw Materials
LIST OF FIGURES
Figure 1. Rare Kidney Diseases Treatment Picture
Figure 2. Global Rare Kidney Diseases Treatment Consumption Value by Drug Class, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class in 2022
Figure 4. Enzyme Replacement Therapy
Figure 5. Monoclonal Antibodies
Figure 6. Others
Figure 7. Global Rare Kidney Diseases Treatment Consumption Value by Drug Class, (USD Million), 2018 & 2022 & 2029
Figure 8. Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel in 2022
Figure 9. Hospital Pharmacies Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Online Sales Picture
Figure 12. Global Rare Kidney Diseases Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Rare Kidney Diseases Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Rare Kidney Diseases Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Rare Kidney Diseases Treatment Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Rare Kidney Diseases Treatment Consumption Value Market Share by Region in 2022
Figure 17. North America Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Rare Kidney Diseases Treatment Revenue Share by Players in 2022
Figure 23. Rare Kidney Diseases Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Rare Kidney Diseases Treatment Market Share in 2022
Figure 25. Global Top 6 Players Rare Kidney Diseases Treatment Market Share in 2022
Figure 26. Global Rare Kidney Diseases Treatment Consumption Value Share by Drug Class (2018-2023)
Figure 27. Global Rare Kidney Diseases Treatment Market Share Forecast by Drug Class (2024-2029)
Figure 28. Global Rare Kidney Diseases Treatment Consumption Value Share by Distribution Channel (2018-2023)
Figure 29. Global Rare Kidney Diseases Treatment Market Share Forecast by Distribution Channel (2024-2029)
Figure 30. North America Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 31. North America Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 32. North America Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 37. Europe Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 38. Europe Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 40. France Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 45. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 46. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value Market Share by Region (2018-2029)
Figure 47. China Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. India Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 54. South America Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 55. South America Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 59. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 60. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. Rare Kidney Diseases Treatment Market Drivers
Figure 65. Rare Kidney Diseases Treatment Market Restraints
Figure 66. Rare Kidney Diseases Treatment Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Rare Kidney Diseases Treatment in 2022
Figure 69. Manufacturing Process Analysis of Rare Kidney Diseases Treatment
Figure 70. Rare Kidney Diseases Treatment Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Figure 1. Rare Kidney Diseases Treatment Picture
Figure 2. Global Rare Kidney Diseases Treatment Consumption Value by Drug Class, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class in 2022
Figure 4. Enzyme Replacement Therapy
Figure 5. Monoclonal Antibodies
Figure 6. Others
Figure 7. Global Rare Kidney Diseases Treatment Consumption Value by Drug Class, (USD Million), 2018 & 2022 & 2029
Figure 8. Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel in 2022
Figure 9. Hospital Pharmacies Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Online Sales Picture
Figure 12. Global Rare Kidney Diseases Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Rare Kidney Diseases Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Rare Kidney Diseases Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Rare Kidney Diseases Treatment Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Rare Kidney Diseases Treatment Consumption Value Market Share by Region in 2022
Figure 17. North America Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Rare Kidney Diseases Treatment Revenue Share by Players in 2022
Figure 23. Rare Kidney Diseases Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Rare Kidney Diseases Treatment Market Share in 2022
Figure 25. Global Top 6 Players Rare Kidney Diseases Treatment Market Share in 2022
Figure 26. Global Rare Kidney Diseases Treatment Consumption Value Share by Drug Class (2018-2023)
Figure 27. Global Rare Kidney Diseases Treatment Market Share Forecast by Drug Class (2024-2029)
Figure 28. Global Rare Kidney Diseases Treatment Consumption Value Share by Distribution Channel (2018-2023)
Figure 29. Global Rare Kidney Diseases Treatment Market Share Forecast by Distribution Channel (2024-2029)
Figure 30. North America Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 31. North America Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 32. North America Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 37. Europe Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 38. Europe Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 40. France Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 45. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 46. Asia-Pacific Rare Kidney Diseases Treatment Consumption Value Market Share by Region (2018-2029)
Figure 47. China Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. India Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 54. South America Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 55. South America Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value Market Share by Drug Class (2018-2029)
Figure 59. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value Market Share by Distribution Channel (2018-2029)
Figure 60. Middle East and Africa Rare Kidney Diseases Treatment Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Rare Kidney Diseases Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. Rare Kidney Diseases Treatment Market Drivers
Figure 65. Rare Kidney Diseases Treatment Market Restraints
Figure 66. Rare Kidney Diseases Treatment Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Rare Kidney Diseases Treatment in 2022
Figure 69. Manufacturing Process Analysis of Rare Kidney Diseases Treatment
Figure 70. Rare Kidney Diseases Treatment Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
